Lynne Lederman, PhD | Authors


Can CDK4/6 Inhibitors Be Optimized for Breast Cancer?

February 25, 2021

Can treatment with inhibitors of cyclindependent kinases 4 and 6 be optimized for patients with breast cancer? This remains an open question 6 years after the first approval of a CDK4/6 inhibitor, palbociclib.

Clinical Trials Are Underway on Novel Approaches to CML-Resistant BCR-ABL1 Inhibitors

November 27, 2020

Agents with novel mechanisms of action distinct from available ATP-competitive tyrosine kinase inhibitors have been tested in patients with previously treated, Philadelphia chromosome–positive chronic myeloid leukemia and offer promise to facilitate deeper remissions.

Incorporating Genomics into Lymphoma Classification Can Improve Care

November 21, 2020

The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.

Big Data–Based Tools Support Cancer Clinical Decision-Making

November 20, 2020

Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.

Low-Level EGFR Variants in NSCLC Detectable by Liquid Biopsy Assays

November 20, 2020

Target capture next-generation sequencing, MassARRAY, and real-time quantitative polymerase chain reaction all effectively detected low frequency somatic epidermal growth factor receptor mutations in cell-free circulating tumor DNA from individuals with non–small cell lung cancer , according to a presentation at the AMP 2020 Annual Meeting and Expo.